Loading
companiesCompany
Protara Therapeutics
Protara Therapeutics is a United States-based biotechnology company running 2 late-stage cancer trials of TARA-002 in bladder & urothelial cancer.
Overview
Protara Therapeutics, based in New York, the United States, is a biotechnology company. Protara is a biopharmaceutical company developing investigational therapies for oncology and rare diseases. On ClinicalTrials.gov it is the lead sponsor of 2 recruiting or active phase 2 and phase 3 interventional cancer trials (1 in phase 3), testing TARA-002 in bladder & urothelial cancer. The largest, NCT07480356 (Efficacy and Safety of Intravesical TARA-002 Compared With Investigator's Choice of Intravesical Chemotherapy in Participants With BCG-naïve High-grade Non-muscle Invasive Bladder Cancer), plans to enrol 284 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.
Headquarters
New York, US
Scorecard
All companies#427of 1244 companies, score 8
- phase 3 +3
- modalities +2
- registry trials +3
0 approved, 1 in phase 3, 0 earlier, 0 targets, 3 registry studies. Formula on the scorecards page.
Type
Stage
Public
Website
Phase 3cell therapy (type not stated)
TARA-002 is an experimental cell therapy whose type is not stated from Protara Therapeutics in phase 3 trials for bladder & urothelial cancer, with its target not yet stated publicly.
Similar pages
- CancerNon-muscle-invasive bladder cancer
Shares Efficacy and Safety of Intravesical TARA-002 Compared With Investigator's Choice of Intravesical Chemotherapy in Participants With BCG-naïve High-grade Non-muscle Invasive Bladder Cancer, Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer, Bladder & urothelial cancer.
cancers
drugs
Phase 3cell therapy (type not stated)
trials
Efficacy and Safety of Intravesical TARA-002 Compared With Investigator's Choice of Intravesical Chemotherapy in Participants With BCG-naïve High-grade Non-muscle Invasive Bladder CancerSafety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer